Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregor Novak

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
European Journal of Gastroenterology & Hepatology|August 18, 2020
Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed labelSebastian Stefanovic, Iris Detrez, Griet Compernolle, et al.
Pharmaceutics|October 23, 2021
Ustekinumab Dosing Individualization in Crohn's Disease Guided by a Population Pharmacokinetic-Pharmacodynamic ModelJurij Aguiar Zdovc, Jurij Hanžel, Tina Kurent, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 29, 2020
Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical RemissionJurij Hanžel, Jurij Zdovc, Tina Kurent, et al.
European Journal of Gastroenterology & Hepatology|February 7, 2025
Directionality of endoscopic and histologic healing in ulcerative colitis: a prospective pilot studyJurij Hanžel, Gregor Novak, Vipul Jairath, et al.
Scandinavian Journal of Gastroenterology|July 11, 2018
Success and safety of high infliximab trough levels in inflammatory bowel diseaseDavid Drobne, Tina Kurent, Sasa Golob, et al.
Alimentary Pharmacology & Therapeutics|April 16, 2019
Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's diseaseGregor Novak, Toer Stevens, Tanja Van Viegen, et al.
European Journal of Gastroenterology & Hepatology|April 16, 2024
Biological treatment approach to inflammatory bowel disease is similar in academic and nonacademic centres - prime time for decentralisation of inflammatory bowel disease care?Katja Tepeš, Jurij Hanžel, David Štubljar, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
European Journal of Gastroenterology & Hepatology|August 18, 2020
Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed labelSebastian Stefanovic, Iris Detrez, Griet Compernolle, et al.
Pharmaceutics|October 23, 2021
Ustekinumab Dosing Individualization in Crohn's Disease Guided by a Population Pharmacokinetic-Pharmacodynamic ModelJurij Aguiar Zdovc, Jurij Hanžel, Tina Kurent, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 29, 2020
Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical RemissionJurij Hanžel, Jurij Zdovc, Tina Kurent, et al.
European Journal of Gastroenterology & Hepatology|February 7, 2025
Directionality of endoscopic and histologic healing in ulcerative colitis: a prospective pilot studyJurij Hanžel, Gregor Novak, Vipul Jairath, et al.
Scandinavian Journal of Gastroenterology|July 11, 2018
Success and safety of high infliximab trough levels in inflammatory bowel diseaseDavid Drobne, Tina Kurent, Sasa Golob, et al.
Alimentary Pharmacology & Therapeutics|April 16, 2019
Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's diseaseGregor Novak, Toer Stevens, Tanja Van Viegen, et al.
European Journal of Gastroenterology & Hepatology|April 16, 2024
Biological treatment approach to inflammatory bowel disease is similar in academic and nonacademic centres - prime time for decentralisation of inflammatory bowel disease care?Katja Tepeš, Jurij Hanžel, David Štubljar, et al.
Pageof 3